M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact BioSpaceMerck will use Protillion Biosciences' tech to design biologic therapies for therapies across undisclosed indications.Read full story pharminent June 17, 2026 (Last updated: June 17, 2026) BioSpace Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. Read full story Post navigation Previous: Moderna builds commercial muscle as new launches loomNext: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
